ACTAVIS PLC |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Sales 2018 | 15.79B 1,315B | Sales 2019 | 16.09B 1,340B | Capitalization | 62.76B 5,228B |
|---|---|---|---|---|---|
| Net income 2018 | -5.1B -425B | Net income 2019 | -5.27B -439B | EV / Sales 2018 | 4.24 x |
| Net Debt 2018 | 21.89B 1,824B | Net Debt 2019 | 17.3B 1,442B | EV / Sales 2019 | 4.98 x |
| P/E ratio 2018 |
-8.76
x | P/E ratio 2019 |
-11.9
x | Employees | - |
| Yield 2018 |
2.15% | Yield 2019 |
1.55% | Free-Float | 99.9% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Alex Thurman
DFI | Director of Finance/CFO | 54 | 01/16/01 |
Robert Michael
PSD | President | 53 | 08/20/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Michael
PSD | President | 53 | 08/20/08 |
Scott Reents
BRD | Director/Board Member | - | 08/20/08 |
Ryan Quigley
BRD | Director/Board Member | - | 08/20/08 |
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 819B | |
| -6.75% | 351B | |
| +13.56% | 329B | |
| +10.68% | 298B | |
| +16.57% | 242B | |
| +2.04% | 225B | |
| +13.31% | 217B | |
| +8.48% | 168B | |
| -2.81% | 158B |
